Kinase inhibitors

Details Kinase inhibitors Kinase inhibitors

2006-04-04

2009-10-06

Wilson, James O. (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C544S224000, C544S336000

Reexamination Certificate

active

07598272

ABSTRACT:
A compound of the general formula:or pharmaceutically acceptable salts, hydrates, solvates, crystal forms or diastereomers thereof is described. A method of treating protein kinase-associated disease states using the compound of formula I is also described.

REFERENCES:
patent: WO-00/62778 (2000-10-01), None
patent: WO-02/060492 (2002-08-01), None
patent: WO-04/004730 (2004-01-01), None
patent: WO-04/085388 (2004-10-01), None
Harpur et al., Oncogene (1992) 7:1347-1353.
International Search Report for PCT/AU03/00628, mailed on Aug. 5, 2003, 3 pages.
Kozma et al.,EMBO Journal (1986) 7(1):147-154.
Sadowski et al., Molecular and Cellular Biology (1986) 6(12):4396-4408.
Spiotto and Chung, The Prostate (2000) 42:88-98.
Wilks and Kurban, Oncogene (1988) 3:289-294.
Wilks et al., Molecular and Cellular Biology (1991) 11(4):2057-2065.
Supplementary European Search Report for EP 03722065.4; mailed on Jun. 6, 2006, 3 pages.
Duhe et al., Cell Biochemistry and Biophysics (2001) 34(1):17-59.
Gavezzotti, Accounts of Chemical Research (1994) 27:309-314.
Vippagunta et al., Advanced Drug Delivery Reviews (2001) 48:3-26.

Affiliated with

Also associated with

Rating

Kinase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Kinase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Kinase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4109562